ChromaCode this week launched its first product, a research-use-only test for nine tick-borne pathogens designed for research use on any thermal cycler.
The researchers are using mass spectrometry to look in patient blood samples for peptides shed by Borrelia burgdorferi, the bacteria that causes Lyme disease.
Using more than 16,000 tick samples submitted by individuals in the mainland US and Puerto Rico, researchers documented tick species and infection by four pathogens.
The CDC says that the number of people in the US who have been infected with diseases carried by mosquitoes, ticks, and flea bites have more than tripled in recent years.
Investigators retraced features contributing to Lyme disease spread by sequencing 146 Borrelia burgdorferi isolates collected in North America since the 1980s.
Researchers used mass spectrometry to identify unique biochemical markers that differentiate Lyme disease from southern tick-associated rash Illness.
The firm remains on track to file for FDA clearance of its T2Bacteria panel, which its CEO called a "game changer" by mid-2017.
Crowdfunding will help move the targeted sequencing-based test through the development process in hopes of commercializing it.
The company said its product revenues rose during the fourth quarter thanks to an increase in T2Candida panel sales due to increased patient testing.
The funds, which the company said are part of a larger $9 million Series A round, will support the development of its test for early diagnosis of Lyme disease.
The US Patent and Trademark Office is opening another interference proceeding in the CRISPR patent fight.
There's increasing genetic evidence that a number of ancient hominins may have contributed to the human gene pool, according to Discover's The Crux blog.
The Japan News writes that Japan needs to seize the opportunity to ensure that a wide number of people benefit from personalized cancer treatments.
In Cell this week: messenger RNA expression and translation, RNA localization atlas, and more.